Basal cell carcinoma - Kansarka Unugyada Basal
☆ Natiijooyinka Stiftung Warentest ee 2022 ee ka yimid Jarmalka, ku qanacsanaanta macaamilka ee ModelDerm ayaa waxyar uun ka hooseysay la-talinta telemedicine-ka ee lacagta lagu bixiyo.
Nabarrada nabarrada ee saameeya maqaarka sanka ee qofka da'da ah waxaa badanaa lagu ogaadaa Kansarka Unugyada Basal (Basal cell carcinoma). Sanku waa goob caadi ah oo uu ka dhaco nooca kansarka maqaarka.
Kansarka Unugyada Basal (Basal cell carcinoma) waxaa laga yaabaa inay la yimaadaan xuduudo iyo boogo aan caadi ahayn.
Kansarka Unugyada Basal (Basal cell carcinoma) waxaa lagu khaldi karaa burooyin.
References
Basal cell carcinoma (BCC) waa nooca ugu badan ee kansarka maqaarka. Soo-gaadhista iftiinka qorraxda ayaa ah sababta ugu weyn. Ku dhawaad dhammaan kiisaska BCC waxay muujinayaan calaamadaynta Hedgehog firfircoon ee falanqaynta molecular. Daawooyin kala duwan ayaa la heli karaa waxaana lagu doortay iyadoo lagu salaynayo khatarta soo noqoshada, muhiimada ilaalinta nudaha, doorbidida bukaanka, iyo heerka cudurka.
Basal cell carcinoma (BCC) is the most common malignancy. Exposure to sunlight is the most important risk factor. Most, if not all, cases of BCC demonstrate overactive Hedgehog signaling. A variety of treatment modalities exist and are selected based on recurrence risk, importance of tissue preservation, patient preference, and extent of disease.
Basal cell carcinoma (BCC) is the most common malignancy. Exposure to sunlight is the most important risk factor. Most, if not all, cases of BCC demonstrate overactive Hedgehog signaling. A variety of treatment modalities exist and are selected based on recurrence risk, importance of tissue preservation, patient preference, and extent of disease.
Basal cell carcinomas waa nooca ugu badan ee kansarka maqaarka ee dadka qaangaarka ah ee maqaarkoodu yahay 50 iyo wixii ka weyn. Tiradooda ayaa kor u sii kacaysa adduunka oo dhan, taasoo ay ugu wacan tahay soo-gaadhista iftiinka qorraxda. Xaalado hiddesiyeedka qaarkood ayaa dadka ka dhigi kara kuwo u nugul inay kansarradan ku dhacaan da'da yar. Basal cell carcinomas way ku kala duwan yihiin darnaanta, oo u dhaxaysa si fudud loo daweyn karo oo dusha sare ah ama nabarrada qanjidhada ah ilaa kuwa aad u ballaaran oo u baahan wadahadal kooxo caafimaad oo takhasus leh. Saadaalku waxay ku xidhan tahay suurtogalnimada inuu kansarku soo noqdo ama awooddiisa inuu waxyeeleeyo unugyada u dhow. Qalliinku waa daaweynta caadiga ah ee kiisaska intooda badan, hubinta ka saarista saxda ah iyo fursadaha soo noqoshada oo yar. Hababka galitaanka yar ayaa si wax ku ool ah u daweyn kara nabarrada kore.
Basal cell carcinomas are the most frequent skin cancers in the fair-skinned adult population over 50 years of age. Their incidence is increasing throughout the world. Ultraviolet (UV) exposure is the major carcinogenic factor. Some genodermatosis can predispose to formation of basal cell carcinomas at an earlier age. Basal cell carcinomas are heterogeneous, from superficial or nodular lesions of good prognosis to very extensive difficult-to-treat lesions that must be discussed in multidisciplinary committees. The prognosis is linked to the risk of recurrence of basal cell carcinoma or its local destructive capacity. The standard treatment for most basal cell carcinomas is surgery, as it allows excision margin control and shows a low risk of recurrence. Superficial lesions can be treated by non-surgical methods with significant efficacy.
Basal cell carcinomas are the most frequent skin cancers in the fair-skinned adult population over 50 years of age. Their incidence is increasing throughout the world. Ultraviolet (UV) exposure is the major carcinogenic factor. Some genodermatosis can predispose to formation of basal cell carcinomas at an earlier age. Basal cell carcinomas are heterogeneous, from superficial or nodular lesions of good prognosis to very extensive difficult-to-treat lesions that must be discussed in multidisciplinary committees. The prognosis is linked to the risk of recurrence of basal cell carcinoma or its local destructive capacity. The standard treatment for most basal cell carcinomas is surgery, as it allows excision margin control and shows a low risk of recurrence. Superficial lesions can be treated by non-surgical methods with significant efficacy.
Daawaynta aasaasiga ah ee BCC waa qalliin. Khatar sare ama soo noqnoqota BCC, gaar ahaan meelaha muhiimka ah, qalliinka micrographically control ayaa lagula talinayaa. Bukaanka leh BCC ee khatarta hoose leh ayaa laga yaabaa inay tixgeliyaan daawaynta jirka la mariyo ama hababka wax burburiya. Daawaynta sawir-qaadista waxay si fiican ugu shaqeysaa korka iyo khatarta hoose ee BCC-yada nodular. BCC maxalli ah oo horumarsan ama dheef-shiid kiimikaad ah, horjoogayaasha Hedgehog (vismodegib, sonidegib) ayaa lagula talinayaa. Haddii uu jiro horusocod cudur ama u dulqaadasho la'aanta ka hortagga Hedgehog, immunotherapy leh anti-PD1 antibody (cemiplimab) waa la tixgelin karaa. Daaweynta shucaaca ayaa ah ikhtiyaar u wanaagsan bukaanada aan la qali karin, gaar ahaan bukaanada da'da ah. Electrochemotherapy waa la tixgelin karaa haddii qaliinka ama shucaaca aysan ahayn doorasho.
The primary treatment for BCC is surgery. For high-risk or recurring BCC, especially in critical areas, micrographically controlled surgery is recommended. Patients with low-risk superficial BCC might consider topical treatments or destructive methods. Photodynamic therapy works well for superficial and low-risk nodular BCCs. For locally advanced or metastatic BCC, Hedgehog inhibitors (vismodegib, sonidegib) are recommended. If there's disease progression or intolerance to Hedgehog inhibitors, immunotherapy with anti-PD1 antibody (cemiplimab) can be considered. Radiotherapy is a good option for patients who can't have surgery, especially older patients. Electrochemotherapy could be considered if surgery or radiotherapy isn't an option.
The primary treatment for BCC is surgery. For high-risk or recurring BCC, especially in critical areas, micrographically controlled surgery is recommended. Patients with low-risk superficial BCC might consider topical treatments or destructive methods. Photodynamic therapy works well for superficial and low-risk nodular BCCs. For locally advanced or metastatic BCC, Hedgehog inhibitors (vismodegib, sonidegib) are recommended. If there's disease progression or intolerance to Hedgehog inhibitors, immunotherapy with anti-PD1 antibody (cemiplimab) can be considered. Radiotherapy is a good option for patients who can't have surgery, especially older patients. Electrochemotherapy could be considered if surgery or radiotherapy isn't an option.
Waxyaabaha halista ah waxaa ka mid ah soo-gaadhista iftiinka ultraviolet, daawaynta shucaaca, soo-gaadhista muddada-dheer ee arsenic iyo hab-dhiska difaaca oo liita (sida xubinta taranka). Soo-gaadhista iftiinka UV inta lagu jiro carruurnimada ayaa si gaar ah waxyeello u leh.
Ka dib marka lagu ogaado biopsy, daaweyntu waxay caadi ahaan tahay ka saarista qaliinka. Tani waxay noqon kartaa goyn fudud haddii kansarku yar yahay; Haddii kansarku aanu yarayn, guud ahaan qalliinka Mohs ayaa lagula talinayaa.
Kansarka unugyada basal-ka ayaa ugu yaraan 32% ka ah dhammaan kansarrada adduunka oo dhan. Kansarrada maqaarka ee aan ahayn melanoma, qiyaastii 80% waa kansarrada unugyada basal-unugga. Dalka Mareykanka, qiyaastii 35% ragga cadaanka ah iyo 25% dumarka cadaanka ah waxaa saameeya kansarka unugyada basal-ka mar noloshooda ka mid ah.
○ ogaanshaha iyo daawaynta
#Dermoscopy
#Skin biopsy
#Mohs surgery